Bicycle Therapeutics PLC

Bicycle Therapeutics reported Q2 2026 financial results, highlighting positive clinical data for nuzefatide and zelenectide, an expanded advisory board, and a cash runway extending into 2030.

Bicycle Therapeutics plc announced that all proposals, including director re-elections and auditor ratification, were approved at its annual general meeting on June 17, 2026.

Bicycle Therapeutics announced encouraging initial Duravelo-2 and updated Duravelo-1 data for metastatic urothelial cancer, showing comparable efficacy to standard of care with a differentiated safety profile.

Bicycle Therapeutics reported Q1 2026 financial results, highlighting progress in nuzefatide development and a strategic reprioritization impacting workforce and pipeline focus.

Bicycle Therapeutics plc announced updates on its nuzefatide pevedotin program and EphA2 pipeline at the AACR Annual Meeting 2026, highlighting encouraging preliminary efficacy and differentiated tolerability.

Bicycle Therapeutics announced a strategic reprioritization, including a workforce reduction, to extend its cash runway into 2030 while focusing on next-generation therapeutics.

Bicycle Therapeutics plc announced its financial results for the second quarter ended June 30, 2026, highlighting a strategic reprioritization of its clinical portfolio and a workforce reduction.

Bicycle Therapeutics plc announced a strategic reprioritization of its clinical portfolio, focusing on nuzefatide pevedotin and next-generation Bicycle conjugates, alongside a workforce reduction of approximately 30%.

Bicycle Therapeutics plc reported increased net losses in Q3 2025, driven by substantial investments in clinical trials and R&D, alongside strategic cost reduction initiatives.

Bicycle Therapeutics plc reported a significantly wider net loss for the second quarter and first half of 2025, alongside a workforce reduction and decreased collaboration revenue, despite advancing its clinical pipeline.

Bicycle Therapeutics reports increased Q1 2025 net loss due to higher research and development expenses, while collaboration revenue declined.

Bicycle Therapeutics reports a net loss of $50.8 million for Q3 2024, while maintaining a robust cash balance of $890.9 million.

Bicycle Therapeutics reported increased net losses in 2025 and announced a strategic reprioritization of its clinical pipeline, including discontinuing certain trials and a 30% workforce reduction, to focus on next-generation therapeutics.

Bicycle Therapeutics' 2024 10-K filing highlights ongoing clinical trials for its Bicycle Toxin Conjugate (BTC) and Bicycle Tumor-Targeted Immune Cell Agonist (TICA) programs, strategic collaborations, and a focus on oncology and radiopharmaceutical development.

Bicycle Therapeutics details its ordinary share structure, shareholder rights, and corporate governance policies in a recent SEC filing.

Travis Alvin Thompson, Chief Financial Officer of Bicycle Therapeutics Plc, received 60,000 shares of common stock on July 15, 2026.

Michael Charles Ferguson Hannay, CHIEF PROD & SUPPLY CHAIN OFF of Bicycle Therapeutics Plc, received 60,000 shares of common stock on July 15, 2026.

Michael Skynner, CHIEF SCIENTIFIC OFFICER of Bicycle Therapeutics Plc, received 60,000 shares of common stock on July 15, 2026.

Jennifer Scott Perry, Chief Operating Officer of Bicycle Therapeutics Plc, received 60,000 shares of common stock on July 15, 2026.

Jennifer Scott Perry, Chief Operating Officer of Bicycle Therapeutics PLC, reported transactions involving the sale of ordinary shares.

Michael Skynner, Chief Scientific Officer at Bicycle Therapeutics, reported transactions involving the sale of company shares to cover tax withholding obligations.

Bicycle Therapeutics plc has announced its 2026 Annual General Meeting will be held on June 17, 2026, to vote on director re-elections, executive compensation, and auditor appointments.

Bicycle Therapeutics is holding its 2025 Annual General Meeting on June 17, 2025, seeking shareholder votes on director re-elections, executive compensation, auditor appointments, and an equity incentive plan amendment.

Bicycle Therapeutics plc announced the appointment of Felix J. Baker, Ph.D. to its Board of Directors and the execution of a registration rights agreement with Baker Brothers funds, granting them certain resale registration rights.

Bicycle Therapeutics has scheduled its 2024 Annual General Meeting (AGM) for May 16, 2024, seeking shareholder approval on key proposals including director re-elections, executive compensation, auditor ratification, and adoption of new articles of association.

Armistice Capital, LLC and Steven Boyd have reported beneficial ownership of 3,398,000 American Depositary Shares of Bicycle Therapeutics plc, representing 6.75% of the class.

Long Focus Capital Management and John Helmers have reported a 6.6% beneficial ownership stake in Bicycle Therapeutics PLC's American Depositary Shares.

Invus Group entities and related parties have reported beneficial ownership of 3.1% of Bicycle Therapeutics plc's ordinary shares as of March 31, 2026.

Westfield Capital Management Company, L.P. has reported a complete divestment of its common stock holdings in Bicycle Therapeutics PLC, reducing its beneficial ownership to zero percent.

Raymond Debbane and affiliated entities, including Invus Public Equities, have disclosed a combined 6.3% beneficial ownership stake in Bicycle Therapeutics plc.

Westfield Capital Management Company, L.P. has reported a complete divestment of its holdings in Bicycle Therapeutics PLC common stock.